[Analysis on prognosis and correlative factors of acute nonlymphocytic leukemia].
To analyze the prognosis and risk factors of acute nonlymphocytic leukemia (ANLL), 94 patients with acute nonlymphocytic leukemia were enrolled in this study, while survival rate and risk factors of prognosis were analyzed. The results indicated that the complete remission (CR) ratio was 51.1%. Overall survival and event-free survival rates of month 6, 12, 18, 24 were 68.6%, 55.8%, 53.8%, 46.4%, 21.3% and 57.9%, 38.6%, 33.3%, 31.6%, 0% respectively. The factors such as age<40 years, WBC<10.0x10(9)/L before chemotherapy, WBC in the period of bone marrow suppression<1.0x10(9)/L, chemotherapy within 1 month after occurrence of leukemia, blood transfusion before chemotherapy of APL had favourable influence on remission and survival rates of ANLL patients. CR1, the time to get CR, length of CR and relapse significantly correlated with prognosis (p<0.05). It is concluded that the individualized therapy concerning the risk factors should be applied to ANLL patients for improving the remission, survival rate and prognosis.
Liu
Chun-Yan
CY
Department of Hematology, The General Hospital, Tianjin Medical University, Tianjin 300052, China.
Fu
Rong
R
Liu
Wen-Hui
WH
Cheng
Yu-Qian
YQ
Song
Wen-Xiu
WX
DU
Li-Juan
LJ
Ruan
Er-Bao
EB
Zhang
Li-Tong
LT
Wang
Xiao-Ming
XM
Liang
Yong
Y
Wang
Guo-Jin
GJ
Qu
Wen
W
Song
Jia
J
Zhang
Rong-Li
RL
Guan
Jing
J
Li
Li-Juan
LJ
Song
Yang
Y
Gao
Shan
S
Liu
Hui
H
Jiang
Hui-Juan
HJ
Wang
Jun
J
Zou
Peng
P
Shao
Zong-Hong
ZH
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006248:Harringtonines / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D014212:Tretinoin / Q000008:administration & dosage / Q000627:therapeutic use; D055815:Young Adult
D006248:Harringtonines; D003561:Cytarabine; C062500:harringtonin; D014212:Tretinoin